NEW YORK (GenomeWeb News) – Seoul-based DNA Link will provide Roche NimbleGen's sequence capture technology as a service in Korea through a coupled offering that includes 454 Life Sciences' sequencing technology, Roche said today.
The Certified Service Provider status enables DNA Link to provide NimbleGen's Titanium Optimized Sequence Capture along with the 454 sequencing, the company said. The sequence capture method is used for genomic enrichment and uses NimbleGen's 385K Arrays.
DNA Link's services include microarrays, next-generation sequencing, and personal genomics, and it has been selected by Korea to provide genotyping for a three-year genome-wide association study. According to Roche, DNA Link is the first genomic service provider to join the global Roche NimbleGen CSP Program.
Financial and further terms of the agreement were not disclosed.